Friday, May 30, 2008
CenterWatch ‘watched’ as more than 60 emerging biotech companies and 125 venture capitalists from across the U.S. converged at the 1st annual BIO National Venture Conference in Boston this week.
U.S. disease foundations invested about $75 million last year in biopharmaceutical companies to fund discovery and development of new drugs and therapies for their corresponding diseases, according to CenterWatch estimates published in the August 2007 issue of The CenterWatch Monthly.
The “Clinical Trials Roundtable” attracted more than 70 participants during the “Science with Africa” conference organized by the United Nations Economic Commission for Africa and the African Union, which is an international organization that promotes cooperation among the independent nations of Africa. The conference was held in Addis Ababa, Ethiopia, and attended by more than 600 representatives, including representatives from health and science ministries, universities, non-governmental organizations and international organizations from Africa, Europe and North America.
The Michael J. Fox Foundation (MJFF) for Parkinson’s Research gets it. They have figured out just how many bottlenecks there are for getting good research out of academia and to the patient. And Michael J. Fox is willing to put its money where it is needed to move along the drug development process.
AstraZeneca’s Japanese subsidiary, AstraZeneca KK, signed a Master Clinical Study Agreement with Keio University School of Medicine based in Tokyo. The university reported that due to Japan’s slow pace of drug research, it has taken steps to build up its own clinical trial capabilities and improve the efficiency of its research.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The New York Academy of Sciences will co-host the inaugural PD Therapeutics Conference on Thursday, October 25, in New York City. This meeting is the first and only major scientific symposium exclusively focused on the development of innovative drugs to target Parkinson’s disease.